MICROVIABLE THERAPEUTICS
Developing microbiome therapies as precision medicine.
Claudio Hidalgo Cantabrana, PhD
Claudio Hidalgo Cantabrana, PhD
Chief Executive Officer and co-founder
Dr. Hidalgo Cantabrana is currently the CEO of Microviable Therapeutics and a member of the board. Claudio obtained his PhD at the University of Oviedo (2015) focused on microbial genetics, probiotics and microbiota, after MS Biotechnology and BS Biology. He has worked in several research international organizations across Europe, and later on we worked over four years at USA.
Over his scientific carrier, he has developed and licensed several patents, published numerous scientific manuscripts and received international fellowships and awards. Claudio is a co-founder of Microviable Therapeutics and the CEO since 2021 leading the company with a strategic vision focused on microbiota-based biotherapeutic products development.
President
Noelia Martínez, PhD
Noelia Martínez Álvarez, PhD
R&D director and co-founder
Dr. Martínez is currently the R&D Director of Microviable Therapeutics and a member of the board. Noelia obtained her PhD at the University of Oviedo (2007) after her BS in Biology. Over her scientific career, she has worked on the genetic basis of multidrug resistant bacteria as human pathogens and later, focused on the use of probiotic bacteria to boost the immune system against microbial pathogens.
Over her scientific career, she has managed numerous projects and collaborations, obtained several patents and scientific manuscripts. Noelia, is currently leading the development of novel technologies and microbiota-based biotherapeutic products as R&D Director of Microviable Therapeutics.
Board member
Rafael M. Permuy, MBA
Rafael M. Permuy, MBA
Chief Business Officer and co-founder
Rafael Permuy is currently the Chief Business Officer of Microviable Therapeutics and a member of the board. Rafael has extensive experience in corporate management and business development. Rafael obtained his MBA at FENA and ESIC Business Schools and his Business Administration and Management Degree at Universidad Católica Santa Teresa de Jesus.
He has developed his professional carrier at multinational companies like Pfizer, Allergan, Sanofi Pasteur MSD and Hartmann with international experience as sales director and management strategies. Later on, he focused his career on startup development and corporate management and has co-founded four biotech companies. He is also an invited professor at the University of Oviedo where he teaches young scientific leaders the basis for biotech development.
Rafael is currently leading Microviable Therapeutics business development, including strategic partnerships and investors relationship.
Board Member
Luis Buznego
Luis Buznego
Board Member
Luis Buznego is an Industrial Engineer (University of Oviedo) with extensive experience in business management and innovation departments. He has been part of the Senior Business Management Program (IESE), is a board member of several companies and Director of the Innovation, Investment and New Opportunities area of IMASA, Engineering and Projects SA. In addition, he is the current Vice President of the Asturian Innovation Club (INNOVASTURIAS) and a member of the investment group PadeInvest 2016 Investments SL.
Board Member
Manuel Monge
Manuel Monge
Board Member
Manuel Monge has made his professional mission to help organizations build better cultures and better leaders. Before joining the Brennan Center where he currently served as Chief Human Resources Officer, Manuel worked at Nestle for 25 years in local, regional, and global roles, across five countries in three different continents. Most recently, Manuel led the Human Resources function for Nestle Health Science in North America, where he helped transform the organization with greater focus on business-oriented HR delivery, employee experience, diversity, equity, and inclusion, performance, and innovation. Manuel holds a BA in Industrial Engineering and an MBA.
Manuel Monge is the Chief Human Resources Officer at the Brennan Center for Justice, a non-profit, non-partisan organization that works to evolve and defend the systems of democracy and justice in the United States. Based in New York City, Manuel serves on the organization’s executive management team, and leads the Brennan Center’s people, organization, and culture initiatives and programs.
Board Member
Mehdi Chouikh Skalli
Mehdi Chouikh Skalli
Board Member
Financial Director with extensive experience in strategic management and financial direction, with a track record of success in co-founding and managing leading companies in their market. Mehdi is a Telecommunications Engineer (2002, University of Málaga) with a Master in Management of Biotech Companies (2010, ESESA). He has been an entrepreneur with the creation of several companies successfully and an investor in a large number of companies.
Board Member
José Vigaray Conde, MD
José Vigaray Conde, MD
Board Member
Specialist in Allergology and Clinical Immunology via MIR at the Hospital Clínico de San Carlos in Madrid, with more than 25 years of healthcare experience in the diagnosis and treatment of asthma and allergic diseases, having been the first head of the Allergology Service Hospital de la Moraleja de SANITAS in Madrid and medical director of Blue Healthcare. Head of the Allergology Unit of the Beata María Ana Hospital in Madrid.
Pioneer in the last decade in the study and treatment of food intolerances and intestinal dysbiosis, being a founding partner and promoter of INMUNOMET. He currently develops his care work at the Beata Hospital (Madrid)
Board Member
Francisco Morís, PhD
Francisco Morís, PhD
Board Member
Francisco Morís has over 25 years of experience in the biotech industry across different roles as a manager, entrepreneur, expert consultant, visiting professor and research scientist. Experienced in both small and large companies, cross-functional team work and coordination, project management, technology transfer and business development. Innovative researcher, strong publication (h-index 34) and patent record (20 families), skilled in business, operational and strategic planning, as well as fundraising from public and private sources.
Built an oncology drug development company from scratch, launching early discovery programs, up to completion of regulatory GLP preclinical studies, alongside with CMC development for GMP manufacturing. Supervised a cross-functional group of scientists, KOLs, CROs and external consultants, teamed up with business development managers to capture external funding, successfully solicited grant awards to fund innovative R&D initiatives.
Francisco received his Ph.D. in 1994 from the University of Oviedo, supervised by Prof Vicente Gotor, and was a postdoctoral fellow in the labs of Prof. Chi-Huey Wong at The Scripps Research Institute in La Jolla (USA). Dr Morís has worked in Biotech (ThermoGen, MediChem, deCode Genetics) and Pharma Companies (Bristol-Myers Squibb) in the United States before launching and leading EntreChem SL, a spin-off company focused on oncology drug development based on synthetic biology, genetic engineering and biocatalysis. Francisco raised >10M€ in public and private funding, positioning EntreChem as the only company in the world with two hybrid natural products close to clinical trials.
Board Member
Abelardo Margolles, PhD
Abelardo Margolles Barros, PhD
Scientific Advisor and co-founder
Professor of Research at IPLA-CSIC
Dr. Margolles is currently a Professor of Research at IPLA-CSIC and is co-founder and scientific advisor of Microviable Therapeutics. Abelardo obtained his PhD at the University Santiago de Compostela (1997) and perform his postdoctoral work at the University of Groningen (1997-2000).
Since he joined IPLA-CSIC in 2000, he has led numerous international projects focused on microbiota and probiotics. Over his successful scientific career, he has developed extensive knowledge on intestinal microbiome and food microbes, specially focused on the probiotic benefits of bifidobacteria and the cross-talk interaction between gut microbiota and human health. He has published more than 200 scientific manuscripts, obtained several patents and is a member of the Spanish Society of Microbiota, Probiotics and Prebiotics (SEMiPyP).
Scientific Advisor and co-founder
Professor of Research at IPLA-CSIC
Susana Delgado, PhD
Susana Delgado, PhD
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC
Dr. Delgado is currently a Principal Investigator at IPLA-CSIC and is co-founder and scientific advisor of Microviable Therapeutics. Susana obtained her PhD in Biology at the University of Oviedo in 2005 with the PhD thesis focused on “Human Intestinal Microbiota: Analyses and evolution of representative bacterial populations and identification of novel probiotics”. Since then, Dr. Delgado has focused her research on human microbiota, particularly on ecology and microbial dysbiosis, leading research projects on intestinal microbiota, health and diet. She has ongoing international projects and collaborations with research centres and clinicians across institutions and countries.
Susana Delgado has published more than 90 scientific manuscripts and is the co-author of several patents, three of them licensed to industry. In 2018, she received the Hipócrates International Award on nutrition Research by the Royal Medicine Academy of Asturias, thanks to her advanced scientific work on IgE non-mediated infant allergy to milk proteins and intestinal microbioma interaction. At present, she is the Coordinator of the Innovation Committee of the Biosanitary Institute of the Principality of Asturias.
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC
Borja Sánchez, PhD
Borja Sánchez, PhD
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC
Dr. Sánchez holds a Principal Investigator position at IPLA-CSIC since 2017 and is co-founder and scientific advisor of Microviable Therapeutics. Borja obtained his PhD at the University of Oviedo (2007) awarded with honors, after his BS in Biology.
He has worked in several international research organizations like INRA – Jouy-en-Josas (France), the University of Parma (Italy) and the International Center of Cooperation in Agronomy (La Réunion). Over his professional career, he has led international projects, published close to 150 scientific manuscripts and is inventor of four patents, three of them licensed to industry.
Borja is currently the Scientific and Innovation Counselor on the Regional Government of Principado de Asturias.
Scientific Advisor and co-founder
Principal Investigator at IPLA-CSIC
Rosa del Campo, PhD, MD
Rosa del Campo, PhD, MD
Scientific Advisor
Dr. Del Campo is a research microbiologist on the clinic at Hospital Ramón y Cajal, Madrid. Rosa obtained her MD at University of Zaragoza (1994) where she also obtained her PhD (1998). She currently holds several positions on the board of different clinical and research organizations like the Human Microbiota Group of the Spanish Society of Infectious Disease and Clinical Microbiology (SEIMC-GEMBIOTA), she is a professor at University Alfonso X el Sabio, and member of the board at Spanish Society of Microbiology (SEM) and SEIMC.
Rosa focused her research on intestinal microbiota and fecal material transplant (FMT) being one of the leaders in Europe and Spain. She has clinical practice on FMT for infectious disease and is developing research on multidrug resistance. Over her successful career she has led several international projects, has received numerous awards and published over one hundred scientific manuscripts. Rosa joined the Scientific Advisory Board of Microviable Therapeutics in 2021 to advance clinical evidence of microbiota-based biotherapeutic products.
Scientific Advisor
Microbiologist at Hospital Ramón y Cajal, Madrid, Spain
Carlos López Otín, PhD, MD
Carlos López Otín, PhD, MD
Scientific Advisor
Dr. Otín is Professor of Biochemistry at the University of Oviedo where he has been leading research in oncology and aging over the past decades. His successful scientific career has led to the discovery of more than sixty human genes unraveling their role in health and disease.
He was part of the first human genome sequencing project and since 2010 he leads the Spanish branch of the international consortium of Cancer Genomes, organization that has identified the mutated oncogenes of hundreds on cancer patients. Carlos latest research includes de discovery of two novel syndromes involved in accelerated aging, the discovery of new genes related with sudden death and hereditary melanoma. Moreover, he has focused several projects on longevity and healthy aging, including the use of specific bacteria that promotes longevity.
Carlos is a member of the European Academy of Science and the Royal Spanish Academy of Science, as well as Honorary Doctor by several international Unviersities. He received numerous awards like Chemistry award by FEBS and the Research National Award “Santiago Ramón y Cajal”. Carlos joined the Scientific Advisory Board of Microviable Therapeutics in 2021 to advance scientific evidence of microbiota-based biotherapeutic products specially focused on longevity and aging.
Scientific Advisor
Professor at University of Oviedo, Spain
Josbert J. Keller, MD, PhD
Josbert J. Keller, MD, PhD
Scientific Advisor
Gastroenterologist at Haaglanden Medical Center
The Hague, Netherlands.
Josbert Keller completed medical school at the University of Amsterdam. Subsequently, he was a PhD fellow at the Department of Pathology at the AMC (University of Amsterdam) in collaboration with the Department of Gastroenterology at the Johns Hopkins University Hospital in Baltimore, investigating molecular alterations in polyposis syndromes.
During his gastroenterology fellowship he became the principal investigator of the FECAL trial, comparing the efficacy of donor feces infusion with conventional antibiotic therapy for patients with recurrent Clostridium difficile infection.In 2015 he was the co-founder of the Netherlands Donor Feces Bank at the Leiden University Medical Center. He is currently involved in research projects addressing stool banking and the effects of FMT for IBD and other disorders.Moreover, he was the project leader of a European standards and guidelines initiative (UEG) about stool banking for FMT. He is (co) author of > 75 publications in peer reviewed scientific journals.
Josbert was the secretary of the Netherlands Society of Gastroenterology between 2011 and 2016, and a representative of the National Societies Forum in the Meeting of Members of the UEG between 2017 and 2020. He is a member of the European Helicobacter and Microbiota Study Group (EHMSG).
Since 2009 he works as general gastroenterologist in The Hague, currently at the Haaglanden Medical Center.
Scientific Advisor
Gastroenterologist at Haaglanden Medical Center
The Hague, Netherlands.
Luis Gosálbez, PhD, MBA
Luis Gosálbez, PhD, MBA
Managing Director at Sandwalk BioVentures
Luis is the Managing Director and Co-Founder at Sandwalk BioVentures, a strategy consulting firm specialized in microbiome technologies. Previously, he held different senior management positions in private and public companies in the biotechnology industry in the UK, Germany and Spain.
He received his BSc and MSc in Biotechnology from Universidad Complutense de Madrid, his PhD in Biology from the Catholic University of San Antonio and a Master’s in Bioscience Enterprise from the University of Cambridge.
Business Advisory Board
Managing Director at Sandwalk BioVentures
Mehdi Chouikh
Mehdi Chouikh, PhD
Chief Financial Officer
Mehdi Chouikh has more than 20 years of experience in strategic management and financial direction, with a track record of success managing top class companies from conception to company acquisitions. Mehdi has been an entrepreneur with the incorporation of several companies successfully, and he is also an investor in a large number of companies from various sectors including biotech. Mehdi is a Telecommunications Engineer (2002, University of Málaga) with a Master in Management of Biotech Companies (2010, ESESA).
Chief Financial Officer
David Ríos Covián, PhD
David Ríos Covián
Director of Technology Development
David obtained his BS in Biology (2010) and MS (2011) in Food Biotechnology at the University of Oviedo. In addition, he obtained his PhD (2016) in Biology by the University of Oviedo with a project focused on metabolic interactions between members of the commensal microbiota. During this stage he gained expertise in several techniques in different international research centers.
Over his scientific career, he has published numerous scientific manuscripts, obtained several scholarships and awards, included the extraordinary thesis award by the University of Oviedo.
His main scientific interest is host-microbiome relationships. During his postdoc at UCSD, he studied these interactions in the context of mucosal immunology and responses to DNA damage. After that, he joined the institute MICALIS (INRAE) to study them in the context of immune system development during early life.
David joined Microviable Therapeutics in 2023 as Director of Technology Development, with the aim of leading the development of new products and the technological platform of Microviable, as well as serving as liaison with public institutions and hospitals collaborating with the R&D area.
Director of Technology Development
Ignacio Montero, PhD
Ignacio Montero, PhD
Computational Biologist
PhD in Microbiology at the University of Oviedo (2014) where he also obtained his BS in Biology (2008). Ignacio has extensive experience in microbiology focused on antimicrobial resistance of human pathogens and on the discovery of novel bioactive compounds in Streptomyces. Lately he has obtained a Certificate in Bioinformatic Analysis at the University Pablo de Olavide (2020) and a MS Degree in Bioinformatics and Biostatistics at the University Oberta of Catalonia (2021).
Over his professional carrier he has obtained several fellowships and published numerous scientific manuscripts. Now he joins the team owning a Torres Quevedo grant (PTQ2020-011411/AEI/10.13039/501100011033) to work on the bioinformatics and comparative genomics platform and give support to the microbiology core team.
Computational Biologist
Pilar Manrique Ronquillo, PhD
Pilar Manrique Ronquillo, PhD
Research Scientist
Pilar obtained her undergraduate degree in Biotechnology at Universidad Francisco de Vitoria (2009) and her doctorate at Montana State University (2018).
Pilar has worked over ten years studying the human gut microbiome. Her research has studied the role of human gut bacteriophages in health and disease and the impact of bacteriophages in the success of fecal microbiota transplant treatment. Moreover, during her postdoc at Ohio State University, she studied the influence of the gut microbiome on the recovery from central nervous system injury.
Pilar joins Microviable Therapeutics in 2022 as Research Scientist to support the R&D area.
Research Scientist
Raquel Marcos Fernández, PhD
Raquel Marcos Fernández, PhD
Research Scientist
Raquel Marcos obtained her PhD from the University of Oviedo (2021) where she also obtained her BS in Biology (2014) and MS in Biotechnology of the Environment and Health (2016). During her PhD, she focused on the study of the gut microbiota and the development of flow cytometry techniques that enable targeted-modification of the microbiota composition to unravel the key biological functions of intestinal bacteria. She has been involved in numerous national and international projects obtaining various scientific publications, communications to scientific symposiums, and she is the coauthor of several patents.
Raquel is currently completing the Diploma of Specialization in Bioinformatics and Computational Genomics at the University of Salamanca and the MS Degree in Innovation in Biomedical and Health Sciences at the University of León. She also holds a MS degree in Occupational Risk Prevention at the University of Francisco de Vitoria (2024).
Raquel joins Microviable Therapeutics in 2024 as a Research Scientist to strength our team and develop novel biological drugs based on bacterial consortia from the microbiota with special focus in oncology and infectious diseases. Raquel has been awarded with a Torres Quevedo grant PTQ2023-012993/MICIU/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation.
Research Scientist
Marta Fernández Gosende, PhD candidate
Marta Fernández Gosende, PhD candidate
Research Scientist
BS degree in Biology (2014) and Food Biotechnology Master (2016) at the University of Oviedo, plus a MS in Microbiota, Probiotics and Prebiotics at the European University at Madrid (2021) with MS thesis focused on probiotics characterization.
Marta has worked in both the private and public sector, with experience in QC departments across several industries, R&D department and academia including IPLA-CSIC. Marta joined Microviable in 2022 as a beneficiary of a national grant Torres Quevedo (DIN2021-012075) from the Spanish Ministry of Science and Innovation to develop the PhD in the industry.
Research Scientist
Alejandro Ojeda
Alejandro Ojeda
Research Scientist
BS degree in Biology (2020) at the University Autónoma of Madrid, and Physiology Masters (2021) at the University of Valencia, his MS thesis focused on the characterization of gut microbiota and its relationship with the Innate Immune System.
Later, he graduated in Clinical and Biomedical Laboratory (2023) at the IES Nº1 of Gijón, with the aim of increasing his skills. Throughout his academic life he has specialized in the fields of human physiology and molecular biology oriented to the study of the microbiota.
Research Scientist
JOIN OUR TEAM
Solid and innovative team
We want to revolutionize the microbiome and probiotics field, and to fulfill this commitment we need intelligent and hardworking people with the desire to join a dynamic team.
Talent, diversity and equality are the core values of our recruitment process and we are continuously looking for motivated people to join our company.
Job description
We are looking for a full-time, highly motivated research assistant / lab technician to work on our team on-site (Oviedo, Asturias, Spain).
The ideal candidate will have experience in microbiology, biochemistry, immunology, microbiota and probiotics, and will join our team to contribute to several research projects towards the development of novel microbiota-derived biological medicines.
About Microviable
Microviable Therapeutics is a preclinical stage biotech company developing a novel class of orally administered biological drugs based on microbiota-derived biotherapeutic products for human health.
Responsibilities
- Collect and process biological samples.
- Propagate and work with microorganisms in different culture conditions.
- Prepare laboratory reagents, culture media and other necessary materials.
- Develop and execute experiments in microbiology, immunology, biochemistry and other areas.
- Monitor and control laboratory stocks.
- Generate, collect and entry experimental data in data bases.
- Support and collaborate in ongoing research projects.
Qualifications
- Laboratory technician qualification.
- Demonstrated experience in microbiology, biochemistry, molecular biology and other relevant areas.
- Ability to execute efficiently in a timely manner.
- Proven ability to carry out experimental assays with a wide range of techniques.
- Highly motivated and organized.
When, where, and how?
- For immediate consideration.
- On-site. In Oviedo, Asturias, Spain.
- Full time.
Benefits
- Competitive salary.
- Holidays improved!.
- Ability to grow in a young and enthusiastic team.
- Free coffee and snacks!!
- Enjoy the beautiful location of Asturias, Spain, with the best combination of a great culture, delicious food and beautiful mountains close to the beach.
If you are interested in working with us, email your credentials at: admin@microviable.com
Description
We are looking for a quality manager to work full-time on-site in Oviedo (Asturias, Spain).
The ideal candidate will have experience in quality departments in biotech or pharmaceutical companies and will join our team to implement, manage and monitor quality standards.
Experience in biological manufacturing facilities and other GMP facilities will be valued positively.
About Microviable
Microviable Therapeutics is a preclinical biotechnology company developing novel microbiota- derived biological medicines for infectious diseases and oncology.
Responsibilities
- Implement, manage, review and maintain quality control documentation.
- Provide quality control oversight to ensure compliance with good laboratory and manufacturing practices.
- Manage quality audits and inspections.
- Develop and implement new quality standards and associated protocols.
- Assists in the development of appropriate standard operating procedures, laboratory data collection and documentation systems (paper and electronic) and
staff training to ensure compliance with implemented standards. - Communicate with the team and ensure implementation of quality control throughout the organization and activities.
Qualifications
- 2+ years of quality control experience in a biotechnology or pharmaceutical industry environment.
- Demonstrated ability to develop and implement quality control strategies.
- Ability to work independently.
- Willingness to work collaboratively in a team environment.
- Fluency in Spanish and English.
When, where and how?
- For immediate consideration.
- In person, in Oviedo, Asturias, Spain.
- Full time.
Benefits
- Competitive salary
- Improved vacations
- Free coffee and snacks!!!
- Enjoy the incredible location of Asturias with the best combination of great culture, delicious food and the sea and mountains right next to your home!
If you are interested in working with us, please email your credentials to: admin@microviable.com
SUBSIDIZED PROJECT
Incentives to Innovative Projects 2023
Project “New Bioactive Ingredients for cosmeceutical applications” Granted by Ayto. de Gijón. Program: Incentives to Innovative Projects 2023 – Business Cooperation Platforms.
Inmunomet Intolerancias y Disbiosis SL
PadeInvest 2016 Investments SL
